Literature DB >> 23448317

Apheresis in three dogs weighing <14 kg.

Lysa P Posner1, Jennifer L Willcox, Steven E Suter.   

Abstract

HISTORY: CaridianBCT apheresis machines require a ~285 mL priming volume (extracorporeal blood) that is withdrawn from the patient in ~10 minutes. Therefore, apheresis in dogs has generally been limited to dogs > ~20 kg to assure <20% of the blood volume is removed in the priming phase. ANIMALS/PHYSICAL EXAMINATION: Three dogs weighing <14 kg (13.6, 10.5, and 9.9 kg) with lymphoma that underwent apheresis. MANAGEMENT: The dogs were premedicated for placement of apheresis catheters with hydromorphone (0.1 mg kg(-1) ) IM. Anesthesia was induced with propofol, to effect, intravenously and general anesthesia was maintained with isoflurane in oxygen. Following catheter placement, dogs were allowed to recover from isoflurane but were kept sedated with either a dexmedetomidine constant rate infusion (CRI) or a propofol CRI. Real time autologous blood priming was not performed in any of the dogs. Instead, priming solutions were composed of a combination of hetastarch, lactated Ringer's solution, and/or autologous blood that was harvested 4 days before the procedure. During apheresis, dogs received anticoagulant citrate-dextrose, solution-A (ACD-A) to prevent clotting and 10% calcium gluconate as needed to maintain normal ionized calcium concentrations. Dogs were monitored for cardiovascular and cardiopulmonary stability, anemia and lactic acidosis. FOLLOW-UP: All of the dogs had cardiovascular and cardiopulmonary values within clinically acceptable ranges. Immediately following apheresis all of the dogs were mildly to moderately anemic (PCV; 17-35%) although none of the dogs required a transfusion or had an increased lactate concentration.
CONCLUSIONS: Dogs as small as 9.9 kg can successfully undergo apheresis with a variety of priming solutions. Dexmedetomidine or propofol given as a CRI provides sufficient sedation for this procedure.
© 2013 The Authors. Veterinary Anaesthesia and Analgesia © 2013 Association of Veterinary Anaesthetists and the American College of Veterinary Anesthesia and Analgesia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23448317     DOI: 10.1111/vaa.12026

Source DB:  PubMed          Journal:  Vet Anaesth Analg        ISSN: 1467-2987            Impact factor:   1.648


  4 in total

1.  Regional Citrate Anticoagulation for Intermittent Hemodialysis in Dogs.

Authors:  T Francey; A Schweighauser
Journal:  J Vet Intern Med       Date:  2017-11-24       Impact factor: 3.333

2.  Renal adenocarcinoma-associated erythrocytosis in a cat: clinicopathological features and immunohistochemical results.

Authors:  Roberta Troia; Chiara Agnoli; Federico Fracassi; Giuliano Bettini; Alessandra Sfacteria; Luciano Pisoni; Francesco Dondi
Journal:  Open Vet J       Date:  2017-10-19

3.  Autologous cancer cell vaccination, adoptive T-cell transfer, and interleukin-2 administration results in long-term survival for companion dogs with osteosarcoma.

Authors:  Brian K Flesner; Gary W Wood; Pamela Gayheart-Walsten; F Lynn Sonderegger; Carolyn J Henry; Deborah J Tate; Sandra M Bechtel; Lindsay L Donnelly; Gayle C Johnson; Dae Young Kim; Tammie A Wahaus; Jeffrey N Bryan; Noe Reyes
Journal:  J Vet Intern Med       Date:  2020-07-10       Impact factor: 3.333

4.  Autologous peripheral blood hematopoietic cell transplantation in dogs with T-cell lymphoma.

Authors:  E E Warry; J L Willcox; S E Suter
Journal:  J Vet Intern Med       Date:  2014-01-27       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.